Circulating ketone bodies and cardiovascular outcomes: the MESA study.
暂无分享,去创建一个
M. Vaduganathan | A. Pandey | J. Yeboah | J. Lima | M. Shapiro | Fàtima Rodríguez | J. Otvos | E. Shemesh | P. Chevli | C. German | M. Blaha | C. deFilippi | Tareq Islam | Michael Blaha
[1] Svati H Shah,et al. Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF , 2022, Circulation.
[2] M. Connelly,et al. Association of Circulating Ketone Bodies With Functional Outcomes After ST-Segment Elevation Myocardial Infarction. , 2021, Journal of the American College of Cardiology.
[3] P. Magni,et al. Reduction of Cardio-Metabolic Risk and Body Weight through a Multiphasic Very-Low Calorie Ketogenic Diet Program in Women with Overweight/Obesity: A Study in a Real-World Setting , 2021, Nutrients.
[4] M. Connelly,et al. Association of beta‐hydroxybutyrate with development of heart failure: Sex differences in a Dutch population cohort , 2020, European journal of clinical investigation.
[5] M. Laakso,et al. Novel biomarkers associated with incident heart failure in 10 106 Finnish men , 2020, ESC heart failure.
[6] P. Ponikowski,et al. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status , 2020, Circulation.
[7] P. Ponikowski,et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.
[8] S. Selvaraj,et al. Implications of Altered Ketone Metabolism and Therapeutic Ketosis in Heart Failure , 2020, Circulation.
[9] K. Clarke,et al. Cardiac ketone body metabolism. , 2020, Biochimica et biophysica acta. Molecular basis of disease.
[10] Sheng-Shou Hu,et al. Elevated plasma β-hydroxybutyrate predicts adverse outcomes and disease progression in patients with arrhythmogenic cardiomyopathy , 2020, Science Translational Medicine.
[11] M. Budoff,et al. N-terminal Pro B-type Natriuretic Peptide and High-sensitivity Cardiac Troponin as Markers for Heart Failure and Cardiovascular Disease Risks According to Glucose Status (from the Multi-Ethnic Study of Atherosclerosis [MESA]). , 2020, The American journal of cardiology.
[12] M. Connelly,et al. Ketone Bodies Are Mildly Elevated in Subjects with Type 2 Diabetes Mellitus and Are Inversely Associated with Insulin Resistance as Measured by the Lipoprotein Insulin Resistance Index , 2020, Journal of clinical medicine.
[13] R. de Cabo,et al. Effects of Intermittent Fasting on Health, Aging, and Disease. , 2019, The New England journal of medicine.
[14] Rick B. Vega,et al. The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense. , 2019, JCI insight.
[15] H. Bøtker,et al. Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients , 2019, Circulation.
[16] Deepak L. Bhatt,et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.
[17] Hiroaki Sunaga,et al. Association Between Circulating Ketone Bodies and Worse Outcomes in Hemodialysis Patients , 2017, Journal of the American Heart Association.
[18] H. Bøtker,et al. Ketone Body Infusion With 3‐Hydroxybutyrate Reduces Myocardial Glucose Uptake and Increases Blood Flow in Humans: A Positron Emission Tomography Study , 2017, Journal of the American Heart Association.
[19] P. Puchalska,et al. Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics. , 2017, Cell metabolism.
[20] A. Pereira,et al. Impact of Exhaled Breath Acetone in the Prognosis of Patients with Heart Failure with Reduced Ejection Fraction (HFrEF). One Year of Clinical Follow-up , 2016, PloS one.
[21] Steffen E. Petersen,et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. , 2016, European journal of preventive cardiology.
[22] J. McMurray,et al. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? , 2016, Diabetologia.
[23] Y. Takeishi,et al. Exhaled Acetone Concentration Is Related to Hemodynamic Severity in Patients With Non-Ischemic Chronic Heart Failure. , 2016, Circulation journal : official journal of the Japanese Circulation Society.
[24] Rick B. Vega,et al. The Failing Heart Relies on Ketone Bodies as a Fuel , 2016, Circulation.
[25] K. Margulies,et al. Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure , 2016, Circulation.
[26] R. Tian,et al. Ketones Step to the Plate: A Game Changer for Metabolic Remodeling in Heart Failure? , 2016, Circulation.
[27] Jason P. Fine,et al. Statistical Primer for Cardiovascular Research Introduction to the Analysis of Survival Data in the Presence of Competing Risks , 2022 .
[28] Yuli Huang,et al. 1H-NMR-Based Metabolic Analysis of Human Serum Reveals Novel Markers of Myocardial Energy Expenditure in Heart Failure Patients , 2014, PloS one.
[29] Eric Verdin,et al. Suppression of Oxidative Stress by β-Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor , 2013, Science.
[30] E. Bocchi,et al. Exhaled acetone as a new biomaker of heart failure severity. , 2012, Chest.
[31] Tuija Tammelin,et al. Metabolic Signatures of Insulin Resistance in 7,098 Young Adults , 2012, Diabetes.
[32] W. Kraus,et al. Metabolic profiles predict adverse events after coronary artery bypass grafting. , 2012, The Journal of thoracic and cardiovascular surgery.
[33] D. Levy,et al. Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. , 2011, The Journal of clinical endocrinology and metabolism.
[34] Eric Boerwinkle,et al. Cardiac Troponin T Measured by a Highly Sensitive Assay Predicts Coronary Heart Disease, Heart Failure, and Mortality in the Atherosclerosis Risk in Communities Study , 2011, Circulation.
[35] J. Polak,et al. Dietary patterns and incident cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis. , 2009, The American journal of clinical nutrition.
[36] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.
[37] Masato Kasuga,et al. [Obesity and insulin resistance]. , 2009, Nihon rinsho. Japanese journal of clinical medicine.
[38] Moyses Szklo,et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. , 2008, The New England journal of medicine.
[39] R. Kronmal,et al. Multi-Ethnic Study of Atherosclerosis: objectives and design. , 2002, American journal of epidemiology.
[40] A. Srivastava,et al. Chronic exposure to beta-hydroxybutyrate impairs insulin action in primary cultures of adult cardiomyocytes. , 2001, American journal of physiology. Endocrinology and metabolism.
[41] J. Levy,et al. Within- and between-subject variation in commonly measured anthropometric and biochemical variables. , 1999, Clinical chemistry.
[42] B. Singh,et al. Insulin resistance in the regulation of lipolysis and ketone body metabolism in non-insulin dependent diabetes is apparent at very low insulin concentrations. , 1993, Diabetes research and clinical practice.